By Holger Adelmann, DIA EMEA
Is Europe geared up to provide an infrastructure to nurture Biotechs? The European Biotechnology Enterprises (EBE) has done a very critical assessment! Is the Pharma sector still attractive for investors or is IT largely eating in? Do we need innovative funding models?
Read more …
Follow Holger on Twitter and LinkedIn for the latest articles